Vomiren-0.075 Injection

About Vomiren-0.075 .075 mg/1.5 ml Injection

Vomiren-0.075 is a prescription injection containing palonosetron, an anti-sickness medicine. It works by blocking a body chemical that triggers nausea and vomiting, and is given by a healthcare professional.

There are 16 brands of Palonosetron listed in Bangladesh.

What is Vomiren-0.075 .075 mg/1.5 ml Injection?

Vomiren-0.075 is an injection that contains palonosetron, a medicine from the anti-emetic group. It is used to prevent and treat nausea and vomiting that can happen after chemotherapy, radiotherapy, or surgery. Palonosetron works by blocking serotonin, a natural substance in the body that can set off the vomiting reflex. The injection is given by a doctor or nurse, usually as a single dose before treatment. The doctor will decide the exact dose and course for each patient. This brand is made by Renata PLC and comes as a 0.075 mg/1.5 ml injection.

Uses of Vomiren-0.075

This medicine is used to control nausea and vomiting in several situations. It helps with acute and delayed nausea and vomiting caused by chemotherapy, including on the day of treatment and on later days. It is also used for nausea and vomiting after surgery and for vomiting that is not controlled by other medicines. It may be used for radiotherapy-related nausea as well. Only a healthcare professional can decide if it is suitable.

How to use Vomiren-0.075

Vomiren-0.075 is given as an injection by a doctor or nurse, usually into a vein. It is not for self-administration at home. The healthcare professional will decide the dose and how fast it should be given, based on the reason it is being used. Always follow the instructions of your doctor or nurse. If you have questions about your dose or schedule, ask your healthcare team.

Side effects of Vomiren-0.075

The most common side effects are headache and constipation. Other side effects may occur, but not everyone gets them. If you notice any unusual symptoms after receiving the injection, tell your doctor or nurse right away. They can advise you on what to do. Do not try to treat side effects yourself without asking a healthcare professional first.

Safety and precautions

Do not receive Vomiren-0.075 if you are allergic to palonosetron or any ingredient in the injection. Before treatment, tell your doctor about all your medical conditions and medicines. If you are pregnant or breastfeeding, ask your doctor first; the medicine is in pregnancy category B, and it is not known if it passes into breast milk. The doctor will decide if it is right for you. There is no known antidote for overdose, so treatment is supportive. Store in a cool, dry place away from light.

Frequently asked questions

What is Vomiren-0.075 used for and what kind of medicine is it?

Vomiren-0.075 is an anti-emetic medicine. It is used to prevent and treat nausea and vomiting caused by chemotherapy, radiotherapy, or surgery. It contains palonosetron and is given as an injection by a healthcare professional.

Who should avoid Vomiren-0.075 or ask the doctor first?

Anyone with a known allergy to palonosetron or any ingredient in the injection should not receive it. If you are pregnant, breastfeeding, or have other medical conditions, ask your doctor before treatment. Always tell your doctor about all medicines you take.

How should Vomiren-0.075 be stored?

Store Vomiren-0.075 in a cool, dry place, protected from light. Keep it out of reach of children. Do not use it after the expiry date. If you have any questions about storage, ask your pharmacist.

Can I give Vomiren-0.075 to myself at home?

No, Vomiren-0.075 is an injection that must be given by a doctor or nurse. It is not for self-administration. The healthcare professional will decide the dose and how it is given. Always follow their instructions.

Indications

Palonosetron indicated in-
  • Acute and delayed nausea and vomiting
  • Uncontrolled nausea and vomiting
  • Chemotherapy-induced nausea and vomiting (CINV): Acute CINV resulting in on the day of treatment with certain types of chemotherapy
  • Delayed CINV resulting in on days later with certain types of chemotherapy
  • ... Read more
Palonosetron indicated in-
  • Acute and delayed nausea and vomiting
  • Uncontrolled nausea and vomiting
  • Chemotherapy-induced nausea and vomiting (CINV): Acute CINV resulting in on the day of treatment with certain types of chemotherapy
  • Delayed CINV resulting in on days later with certain types of chemotherapy
  • Radiotherapy-induced nausea and vomiting (RINV)
  • Post-operative & Post-discharge nausea and vomiting (PONV & PDNV).

Pharmacology

Palonosetron is a 5-HT3 receptor antagonist with a strong binding affinity for this receptor and little or no affinity for other receptors. It is thought that chemotherapeutic agents produce nausea and vomiting by releasing serotonin from the enterochromaffin cells of the small intestine and that the released serotonin then activates 5-HT3 receptors that are located on the nerve terminals of the vagus in the periphery and centrally in the chemoreceptor trigger zone of the area postrema, to initiate the vomiting reflex. Postoperative nausea and vomiting is influenced by multiple patient, surgical and anesthesia related factorcs and is triggered by release of 5-HT3 in a cascade of neuronal event involving both the central nervous system and the gastrointestinal tract. The 5-HT3 receptor has been demonstrated to selectively participate in the emetic response. Palonosetron works by blocking the actions of Serotonin, associated with nausea and vomiting, at 5-HTs receptor. It is likely that Palonosetron works in the small intestine but it may also work in the brain.

Pharmacokinetics: Palonosetron exhibits linear dose-proportional pharmacokinetics over the doserange 1-90 pg/kg in healthy subjects and in patients with cancer. In cancer patients receiving single intravenous doses of Palonosetron in this dose range, the mean maximum plasma concentration (Cmax) ranges from 0.89 to 336 ng/ml and the area under the plasma concentration-time curve from zero to infinity (AUCo-co) ranges from 13.8 to 957 ng.h/ml. Palonosetron has a volume of distribution of approximately 6.9-7.9 L/kg, with approximately 62% bound to plasma proteins. Approximately 50% of Palonosetron is metabolized into two inactive metabolites that exhibit <1% of the 5-HT3 receptor antagonist activity. Approximately 40% of the drug is metabolised via kidney, 50% by liver CYP2D6 (mainly), CYP3A4 and CYP1A2 isoenzymes. About 50% of the drug goes under metabolism. After a single intravenous dose, approximately 40% is excreted as unchanged drug in the urine after 144 hours. Total body clearance of Palonosetron is 160±35 ml/h/kg, and renal clearance is 66.5±18.2 ml/h/kg in healthy subjects. Palonosetron exhibits a longer half-life (40 hours) and has a greater 5-HT3 receptor binding affinity.

Dosage & Administration

Usual dosage: Adult tablet dosage: 0.5 mg daily. Adult IV dosage: A single IV dose of 0.075 mg should be administered over 10 seconds.

Chemotherapy-induced nausea and vomiting: Adult tablet dosage: 0.5 mg administered approximately 1 hour prior to the start of chemotherapy. Adult IV dosage: A single IV dose of 0.25 mg should be administered over 30 seconds approximately 30 minutes before the start of chemotherapy.

Radiotherapy-induced nausea and vomiting: A single IV dose of 0.25 mg should be administered over 30 seconds approximately 30 minutes before each week of radiation fraction.

Post-operative nausea and vomiting: A single IV dose of 0.075 mg should be administered over 10 seconds immediately before induction of anesthesia.

Children dosage: (1 month to 17 years): A single IV dose at 20 mcg/kg body weight. Which maximum dose is 1.5 mg.

Interaction

In controlled clinical trials, Palonosetron injection has been safely administered with corticosteroids, analgesics, antiemetics/antinauseants, antispasmodics and anticholinergic agents. Palonosetron did not inhibit the antitumor activity of cisplatin, cyclophosphamide, cytarabine, doxorubicin and mitomycin C in murine tumor models. Concomitant administration of Palonosetron and metoclopramide has no significant pharmacokinetic interactions. In vitro studies indicated that palonosetron is not inhibitor of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, CYP2E1 & CYP3A4/5 (CYP2C19 was not investigated) nor does it induce the activity of CYP1A2, CYP2D6 or CYP3A4/5. Therefore, the potential for clinically significant drug interactions with Palonosetron appears to be low.

Contraindications

Palonosetron is contraindicated in patients known to have hypersensitivity to the drug or any of its components.

Side Effects

The most common adverse reactions are headaches and constipation.

Pregnancy & Lactation

Pregnancy category 'B'. It is not known whether Palonosetron is excreted in breast milk.

Overdose Effects

There is no known antidote to Palonosetron. Overdose should be managed with supportive care.

Storage Conditions

Store in a cool & dry place, protected from light.

Alternative brands of Palonosetron

Other brands with the same generic name, cheapest first.

See all 16 brands

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.